The introduction of second-generation androgen receptor antagonists (SG-ARAs) has
greatly impacted the treatment of metastatic prostate cancer, providing tolerable and …

Oral abiraterone acetate (Zytiga®) is a selective inhibitor of CYP17 and thereby inhibits
androgen biosynthesis, with androgen signalling crucial in the progression from primary to …

Background The aim of the study was to evaluate whether the use of chemotherapy in
combination with naringin, a dietary plant polyphenolic flavonoid, could enhance the …

Background Androgen deprivation therapy is a first-line treatment for disseminated prostate
cancer (PCa). However, virtually all tumors become resistant and recur as castration …

Simple Summary Prostate cancer (PCa) is the second most common cancer and the second
leading cause of cancer deaths in US men. Resistance to standard medical castration and …

The Hippo pathway regulates and contributes to several hallmarks of prostate cancer (PCa).
Although the elucidation of YAP function in PCa is in its infancy, emerging studies have shed …

Aims: Among patients diagnosed with prostate cancer, 10–20% will develop castration-
resistant prostate cancer (CRPC) within 5 years; for 70%, CRPC will metastasize, mostly to …

Background There is little information available on health-related quality of life in patients
with chemotherapy-naïve metastatic castration-resistant prostate cancer. This study aimed to …

The overall goal of this study was to elucidate the role of FGFR1 induction in acquired
resistance to MET and VEGFR2 inhibition by cabozantinib in prostate cancer (PCa) and …

Patient-derived explant (PDE) culture of solid tumors is increasingly being applied to
preclinical evaluation of novel therapeutics and for biomarker discovery. In this technique …